APG-3288

N/A

Report date: 2026/03/27 20:01:50
NME

Base Information

Drug NameAPG-3288
Drug Alias NameAPG-3288APG3288
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionTyrosine-protein kinase BTK degraders
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsHematologic NeoplasmsWaldenstrom MacroglobulinemiaLymphoma, Mantle-Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSuzhou Ascentage Pharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAscentage Pharma Group InternationalAscentage Pharma Group IncSuzhou Ascentage Pharma Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsWaldenstrom MacroglobulinemiaLymphoma, Mantle-Cell +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A